Freeze-Dried Platelets Could Be the First Drug to Treat Brain Swelling After Traumatic Injury

The blood-brain barrier is one of the body’s more elegant feats of engineering. A continuous sheath of specialized cells lining the brain’s tiny vessels, it keeps circulating blood (along with anything dissolved in it) out of neural tissue, while allowing oxygen and glucose to pass freely through. For most of your life, the system works without drama. Then a car hits you. Or you fall. Or a blast wave moves through the air faster than you can perceive it. Within hours, sometimes within minutes, those tightly sealed cells begin to loosen. Blood leaks into brain tissue. White cells, never supposed to be there, start forcing their way through vessel walls. The brain swells, and doctors, faced with a rising tide of pressure inside the skull, have almost nothing pharmaceutical to offer.

That therapeutic vacuum has persisted for decades, which is what makes a new set of findings from UC San Francisco worth paying attention to. Researchers there have found that a freeze-dried blood product, originally designed to stop battlefield bleeding, can patch damaged vessels in the brain, reduce hemorrhage, and suppress the inflammatory cascade that causes the brain to swell in the days after injury. If the results translate to people, it might finally give emergency teams something they have never had: a drug-like treatment for traumatic brain injury that could be stored for years on an ambulance shelf.

A Problem With Few Good Options

Traumatic brain injury is the leading cause of death in children and adults aged 18 to 44, with roughly 2.8 million cases and more than 69,000 deaths in the United States each year. Falls, car accidents, violence, sports impacts. The immediate bleeding kills some patients; others survive the first impact only to deteriorate days later as the blood-brain barrier collapses and the brain floods with inflammatory cells. Surgeons can remove part of the skull to relieve the pressure, and osmotic agents like mannitol can pull water out of tissue temporarily, but those are blunt tools. “In some cases, surgeons will remove part of the skull to relieve the pressure, but there’s no drug that effectively treats swelling, or cerebral edema, directly,” says Shibani Pati, director of the UCSF Center for Research Transfusion Medicine and Cell Therapies and senior author of the study.

The product at the centre of the work, known as Thrombosomes, is made from freeze-dried platelets (the blood cells responsible for clotting) using a sugar called trehalose to preserve their contents during the drying process. Shelf life: up to five years, compared with the seven-day window for conventional fresh platelets, which also require refrigeration. It was developed originally to control hemorrhage in battlefield settings where blood bank supplies are unavailable. What no one had really tested was whether it could do anything useful inside the skull.

From the Lab Dish to the Injured Brain

The UCSF team worked across several experimental systems. In petri dishes, they applied the product to brain microvascular endothelial cells, the building blocks of the blood-brain barrier, and watched the cells grow significantly more resistant to permeability-inducing agents like thrombin and TNF-alpha. In 3D organoid models of the BBB, constructed from endothelial cells, pericytes and astrocytes arranged to mimic the real structure, the product again reduced the leakage of fluorescent dye through vessel walls. Both results are somewhat routine for in vitro work. The mouse experiments are where things got more interesting.

Using a controlled cortical impact model (basically, a precisely calibrated mechanical blow to the exposed brain surface), the researchers induced moderate-to-severe traumatic brain injury in adult mice, then administered the freeze-dried platelet product either two hours or 24 hours afterward. Three days post-injury, the treated animals had significantly less hemorrhage at the injury site, better blood flow through the fine cerebral capillaries, and far fewer inflammatory immune cells infiltrating brain tissue. “Platelets carry many potent factors that go beyond clotting,” Pati says. “In our mouse model of TBI, we saw hints that this product concentrates these factors, making it more effective than platelets themselves.”

A Molecular Tourniquet for Leaking Vessels

That last observation is perhaps the most intriguing part of the story. Fresh platelets, the obvious comparison, offered no protection to the blood-brain barrier in this model. None. The freeze-drying process, it seems, concentrates specific bioactive proteins from the platelet interior, producing a substance that performs rather differently from its source material. Through proteomic analysis, the team found that the freeze-dried product is particularly rich in angiopoietin-1, a protein that activates a receptor on endothelial cells called Tie2. That signalling pathway acts as a kind of molecular tourniquet on blood vessels, stabilising their walls and preventing leakage. When the researchers blocked the Tie2 receptor in TBI mice using a decoy peptide, barrier permeability got worse; giving the freeze-dried product alongside the blocker partially restored protection, confirming that angiopoietin-1 is at least one active agent in what could turn out to be a larger cocktail of useful molecules.

The inflammatory picture was also striking. Beyond hemorrhage, TBI mice treated with the product had markedly reduced activation of microglia (the brain’s resident immune cells) and far fewer infiltrating macrophages in the injury core and surrounding penumbra. Transcriptomic profiling of cortical and hippocampal tissue revealed downregulation of hundreds of genes involved in inflammation and fibrosis: vimentin, TGF-beta1, integrins implicated in scarring. Astrocyte reactivity, another hallmark of serious brain trauma, was dampened across multiple brain regions. Whether those molecular changes translate into better long-term neurological outcomes in animals, let alone in people, remains to be tested; the current study was scoped to three days post-injury.

The Limits, and the Path Forward

There are honest limitations here worth noting. The study used only one injury model, controlled cortical impact, which is reproducible and clinically relevant but cannot capture the full spectrum of real-world TBI: blast injuries, penetrating wounds, diffuse axonal damage. Only male mice were studied, which the authors justify partly by citing CDC data showing men are nearly three times more likely to die from TBI than women, though that reasoning doesn’t make female physiology irrelevant to eventual clinical translation. And the behavioral correlates of improved vascular biology were not assessed.

Still, the product has a practical advantage that most experimental TBI therapies lack. Thrombosomes have already completed Phase II clinical trials for bleeding disorders, which means safety data in humans exists. That shortens the regulatory runway considerably. And a shelf-stable biologic that requires no cold chain could be carried on military helicopters, rural ambulances, or stocked in emergency departments where fresh blood products are never reliably available: the precise settings where severe traumatic brain injury is most likely to go undertreated.

Whether platelets, even freeze-dried ones, will ever be thought of primarily as a brain drug is a genuinely strange idea. But the science behind the barrier keeps pointing the same direction. The brain is not just a clot waiting to happen at the wrong moment; it is a vascular organ as much as anything else, and the vessels that supply it can apparently be stabilised, perhaps even recruited into the repair process, if you know what to give them. The next step is figuring out whether what works in mice three days after a blow to the head will work in people who have just survived the worst moments of their lives.

Study: https://doi.org/10.1182/blood.2025031826

Frequently Asked Questions

Why can’t doctors currently just give someone a drug to reduce brain swelling after a head injury?

The short answer is that nothing approved actually works well enough. Surgeons can reduce pressure by removing part of the skull, and osmotic agents like mannitol temporarily draw fluid out of tissue, but neither addresses the underlying reason the brain swells: damaged blood vessels leaking fluid and inflammatory cells into neural tissue. Decades of drug trials targeting cerebral edema have largely failed, which is why researchers are now looking at biologics like platelet-derived products that can interact directly with the vessel wall.

How is a freeze-dried platelet different from a normal platelet transfusion?

The freeze-drying process, done in the presence of the sugar trehalose, strips away the cell’s outer structure while concentrating certain proteins from inside it. The result behaves differently enough from fresh platelets that in mouse models of brain injury, fresh platelets offered no protection to the blood-brain barrier while the freeze-dried version did. The product appears to be particularly enriched in angiopoietin-1, a vascular-stabilising protein that is naturally depleted after trauma, which could explain much of the effect.

Could this actually be kept on ambulances or in remote clinics?

That is precisely the appeal. Fresh platelets have a shelf life of about seven days and need to be kept at room temperature with constant agitation, which makes them impractical outside well-equipped hospitals. The freeze-dried version has a shelf life of up to five years at room temperature, requires no cold chain, and can be reconstituted with sterile water. Whether the logistics work in practice depends on regulatory approval and further clinical trials, but the storage profile is genuinely compatible with prehospital and remote settings.

What is the Tie2 receptor and why does it matter for brain injury?

Tie2 sits on the surface of endothelial cells, the cells that line blood vessels, and acts as a stability switch: when activated by angiopoietin-1, it tightens junctions between cells and reduces vessel leakiness. After traumatic brain injury, angiopoietin-1 levels drop and its counterpart, angiopoietin-2, rises, tipping the balance toward permeability and inflammation. The UCSF study is among the first to show that directly targeting this pathway after TBI can meaningfully protect the blood-brain barrier, which opens up a broader class of possible therapies beyond platelets alone.

How far is this from being used in people with brain injuries?

Further than the headlines might suggest, but closer than a completely new drug would be. Thrombosomes have already completed Phase II clinical trials in people with bleeding disorders, so the basic safety profile in humans is established. The researchers will need to run trials specifically for TBI, likely first testing safety and then efficacy, and will need to demonstrate that the vascular improvements seen in mice three days after injury translate into meaningful neurological outcomes in people. That process typically takes years, though the existing clinical data shortens the path somewhat.